Corey Kasimov

“What are the key factors that are going to drive your future treatment choices between Obexi and Uplizna? What would make you choose one product versus another for a particular patient?”

“So, I want to ask about your Phase 3 frontline PDAC studies. For patients that end up in a control arm, how do you plan to assess those that drop out potentially even after receiving just a single dose of chemo and then eventually go on to receive commercial directs on RASIB upon approval?”

“Wanted to ask about an accident in the amplitude study and what kind of data would be necessary in that interim analysis to file for accelerated approval? Basically, like, what constitutes a win with this first data look?”

“From the market research you've done in Mycena Gravis, what percent of the market is currently served by IV C5 therapies, and do you expect a robust switch market to develop when some discerin reaches the market before the end of the year?”

“I wanted to follow up on Selvyn's question on Anaxapaline. And when you think about the pending data from Amplified looking at AMKD patients with moderate proteinuria or diabetes, what's needed in this population for a clinically meaningful benefit to justify advancement in this patient segment?”